Aug. 21 at 10:43 AM
Jefferies assumed coverage on
$SRRK at a Buy rating and a
$50 price target.
$RHHBY -
$PTCT $BIIB -
$IONS NVS BHVN
Jefferies said in its research note:
We expect apitegromab to be approved in SMA (broad label in ≥2y, types 1-4, ambulatory/non-ambulatory) w/ pot'l 1Q PDUFA delay (currently Sept 22) due to procedural observations from recent FDA site inspection.
We model
$1.8B risk-adj PS (POS 90% in ≥2y & 50% in <2y).
Outside SMA, we see optionality w/ api/SRK-439 in other neuromuscular disorders (DMD/FSHD) & obesity (via partnership).
